Starbucks has decided to stop paying for popular weight-loss injections. The change takes effect in October. Employees who qualify for company health plans will no longer get coverage for GLP-1 medications when doctors prescribe them solely to shed pounds. Coverage remains for diabetes and other approved medical uses. The coffee chain joins a growing list of big employers tightening their belts on one of the most talked-about benefits of the past few years.
This reversal comes as spending on these drugs has exploded. Business Insider first reported the move on August 7. A Starbucks spokesperson confirmed the policy shift but offered no further comment. The company provides health benefits to both full-time and part-time workers who log at least 20 hours a week. That generous stance once set Starbucks apart. Now cost pressures are forcing adjustments.
GLP-1 drugs first gained approval for type 2 diabetes. Their ability to curb appetite turned them into a sensation for obesity treatment. Demand surged. So did the price tag. Last year these medications made up 11.4 percent of total annual claims for corporate health plans. That figure stood at just 6.9 percent in 2023 according to a survey by the International Foundation of Employee Benefit Plans. Thirty-six percent of employers covered the drugs for both diabetes and weight loss in 2026. Another 60 percent limited coverage to diabetes only.
Broader health costs are climbing too. Average per-employee benefit expenses rose 6 percent last year. They are forecast to increase 6.7 percent this year. Mercer identified the rapid uptake of GLP-1 drugs as one of the biggest factors pushing those numbers higher. Employers face tough choices. Continue funding the benefit and watch premiums spike. Or scale it back and risk employee pushback.
Other companies have already drawn the same line.
Allina Health, a Minnesota health system, ended coverage for weight-loss versions of these drugs in January 2025. Executives warned that keeping the benefit would drive significant premium increases. PwC reportedly followed a similar path. Yet not every organization is pulling away. Bank of America chief executive Brian Moynihan told investors earlier this year that the bank spends more than $250 million annually on GLP-1 coverage. That represents roughly 13 percent of its $2 billion healthcare budget. He framed the expense as a direct investment in workforce health.
The Starbucks decision reflects wider tension. On one side sit employees who see these drugs as life-changing. Studies show meaningful reductions in weight and related chronic conditions. On the other sit finance teams staring at soaring pharmacy bills. A June report from CNBC highlighted that nearly half of large employers covered GLP-1s for weight loss in 2025. By 2026 that share had slipped. Six percent of firms with 500 or more workers dropped coverage entirely this year. Another 5 percent are considering cuts for 2027. The Business Group on Health found 10 percent of companies currently offering the benefit view continuation as unlikely next year purely for cost reasons.
Recent data adds fresh perspective. A Gallup survey released in early August showed 11 percent of American adults now use GLP-1 medications for weight management. That is up sharply from 3 percent in 2024. Obesity rates have ticked downward in tandem. Doctors caution that off-label use and supply issues persist. Meanwhile food and beverage companies feel secondary effects. An Ohio State University study published in July by the Columbus Dispatch documented reduced dining out among users who eat less, share plates, and skip dessert. JPMorgan analysts project the GLP-1 boom could shave $30 billion to $55 billion annually from food and beverage revenues by the early 2030s as consumers cut calorie intake by 21 percent.
Starbucks itself has tried to adapt on the sales side. In February chief executive Brian Niccol pointed to rising GLP-1 adoption as a reason for the company’s increased focus on high-protein menu items. The chain wants to capture demand from customers seeking satisfying options that align with lower overall calorie consumption. That strategic pivot now sits alongside a benefits policy moving in the opposite direction.
Pharmaceutical manufacturers have responded to criticism over pricing. Novo Nordisk cut list prices on Wegovy and Ozempic by as much as 50 percent earlier this year. Eli Lilly has introduced oral formulations that could reach pharmacies soon. These steps may ease some pressure. Yet employer budgets remain stretched. Analysts expect further plan design changes. Some companies add step therapy requirements. Others impose strict body-mass-index thresholds or mandate participation in lifestyle programs before approving coverage.
The Starbucks announcement arrives at a moment when public conversation around these drugs has matured. Early hype around rapid weight loss has given way to discussion of long-term maintenance, potential side effects, and equitable access. For benefits professionals the math is stark. One year of treatment can exceed $12,000 before rebates. When thousands of employees qualify the total hits millions quickly. And once started many patients stay on the drugs indefinitely to maintain results.
But the human element matters too. Employees who have lost significant weight report higher energy, fewer sick days, and better chronic-disease management. Those gains translate into productivity. The question is whether employers can afford to keep subsidizing them at current levels. Starbucks has opted for a middle path. Coverage continues for diabetes. Weight-loss prescriptions shift to cash-pay or alternative insurance. Part-time baristas who rely on the company plan will feel the change most acutely.
Industry watchers predict more announcements like this one before year-end. The Mercer and Business Group on Health surveys both signal continued retrenchment. At the same time newer oral GLP-1 pills expected in late 2026 or 2027 could alter cost dynamics again. Lower manufacturing expenses and broader competition might bring prices down. Until then employers are voting with their plan documents. Starbucks has cast its ballot. Others are watching closely.
Starbucks Halts Weight-Loss Drug Coverage as Employer Bills Surge first appeared on Web and IT News.